Published in Pharma Investments, Ventures and Law Weekly, March 20th, 2005
The company's financial results reflect an increase in clinical-development activity as phase II/III programs in ragweed allergy immunotherapy and in hepatitis B prophylaxis advanced, as well as activity related to earlier-stage preclinical programs, which are in line with the company's goals and expectations.
As of December 31, 2004, Dynavax reported that cash, cash equivalents, and marketable securities totaled $65.8 million compared to $71.5 million at September 30, 2004 and $29.1 million at December 31, 2003. The increase in cash from 2003 to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.